DNAPrint genomics Chairman Hector Gomez Tells Annual Meeting That Company Broadens Its Activities

DNAPrint genomics Chairman Hector Gomez Tells Annual Meeting That
Company Broadens Its Activities
Focusing on Three Business Segments: Pharmacogenomics, Forensics, Ancestry



SARASOTA, Fla., June 24  /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc.
(OTC:DNAP) (BULLETIN BOARD: DNAP)  Chairman and Chief Medical Officer Hector J.
Gomez, M.D., Ph.D., told shareholders attending the Annual Meeting yesterday
that "the Company's science is the platform technology that will lead to
customized medicine, which we believe is the next truly important step in
identifying, treating and healing diseases. Great advances in medicine have
been made by brilliant doctors and researchers at universities, hospitals and
pharmaceutical companies. The mission of DNAPrint genomics and its scientist
founders is to maximize these accomplishments by providing doctors a blueprint
for the efficacy of various drug treatments, which may vary from person to
person with the same disease because of differences in DNA.

"We have put a new face on DNAPrint," Dr. Gomez said.  "DNAPrint has
successfully leveraged its expertise in DNA technology into the development of
pharmacogenomics, in particular, test/drug combinations called 'theranostics.'
In addition, we will continue to expand our line of forensic products for the
law enforcement market, as well as family ancestry products for individual
consumers."

Shareholders attending the Annual Meeting and those voting by proxy approved an
amendment to the Company's Articles of Incorporation to effect a stock
combination of at least 1-for-10 but no more than 1-for-20 with the exact ratio
to be established by the Board of Directors at the time it elects to effect the
combination.  The purpose for the stock combination is to be able to access up
to $40 million in growth capital that has been committed to DNAPrint over the
next two years so that the Company can implement its strategic plans for
building both its pharmaceutical and forensics divisions. In its pharmaceutical
division, DNAPrint will seek to accelerate the development of PT-401, a
longer-acting and more potent compound for the anemia drug erythropoietin
(EPO), to license new compounds to broaden its pharmaceutical product pipeline,
and to accelerate development of its diagnostic testing products. The goal of
the forensics division is to create a fully functional and certified forensics
laboratory -- either through expansion of the Company's existing facilities or
through acquisition.

Dr. Gomez, in an overview of the Company's activities, noted that DNAPrint
already has a project under way to develop a new, more potent and long-acting
form of the erythropoietin. Working in collaboration with Harvard Medical
School's Beth Israel Deaconess Medical Center (BIDMC), DNAPrint has begun pre-
clinical work on PT-401, a "Super EPO" that would be the Company's first
Investigational New Drug (IND) once an application is filed with the U.S. Food
and Drug Administration.

Dr. Gomez stated that drugs of the future will be comprised of test/drug
combinations for ensuring efficacy with genetically compatible patients.
"Theranostics have the potential to reduce adverse patient reactions to new
drugs," he said.  "Determining beforehand whether a patient will respond
positively or negatively to a new drug could save them from undergoing
treatments that might be ineffective, debilitating, or even life threatening."

DNAPrint Founder and Chief Scientific Officer Tony N. Frudakis, Ph.D., said
that scientists and physicians have known for many years that there are
inherited genetic differences across global populations and even between and
among family members.  "These differences are what we all celebrate as our
cultural heritage," he said. "Unfortunately some of our genetic heritages often
bring prevalence for disease and inabilities to metabolize medicines. Our goal
is to develop a genetically based diagnostic assay protocol that enables
physicians to prescribe drugs more effectively."

DNAPrint also has two other pharmacogenomic products under development. It is
working with the H. Lee Moffitt Cancer Center on the development of
OVANOME(TM), a test for predicting an ovarian cancer patient's response to
TAXOL/Carboplatin treatment, and STATINOME(TM), a test for predicting adverse
response to cholesterol lowering medicines known as Statins. "Our DNA
technology is advancing into new areas while we continue to develop our core
genealogy business," Dr. Frudakis said.

DNAPrint also has a growing product line for the forensics market and recently
announced that it has begun research with Penn State University on developing
3D biometric applications for the Company's DNAWITNESS(TM) product for law
enforcement. It also is completing beta trials on a DNAWITNESS test kit that
enables forensics experts to conduct their own tests without sending recovered
DNA back to the Company for analysis.  In 2004, DNAPrint introduced
RETINOME(TM), another valuable tool for forensics investigators which can
determine human iris (eye) color from DNA samples.

Dr. Frudakis noted that in 2004 the Company added a new test, EURO-DNA(TM) 1.0,
to complement its existing ANCESTRYbyDNA(TM) product targeting consumers who
want to learn about their family heritage.

In other action, shareholders re-elected the three-member Board of Directors
consisting of Dr. Gomez, Dr. Frudakis and Richard Gabriel, President and Chief
Executive Officer.

Shareholders also ratified the selection of Pender, Newkirk and Company as the
Company's independent auditors for the fiscal year ending Dec. 31, 2005.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com/ ) is a developer of
genomics-based products and services focused on drug development,
pharmacogenomic diagnostic tests, forensics technology and consumer genetic
tests. The Company's first theranostic product (drug/test combination) is PT-
401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia
in renal dialysis patients (end stage renal disease). Currently in pre-
clinical development, PT-401 will be targeted to patients with a genetic
profile indicating their propensity to have the best clinical response.

Forward-Looking Statements

All statements in this press release that are not historical are forward-
looking statements. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected,
including, but not limited to, uncertainties relating to technologies, product
development, manufacturing, market acceptance, cost and pricing of DNAPrint's
products, dependence on collaborations and partners, regulatory approvals,
competition, intellectual property of others, and patent protection and
litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any forward-
looking statements contained herein to reflect any change in DNAPrint's
expectations with regard thereto or any change in events, conditions, or
circumstances on which any such statements are based.

   Company Contact:
   Hector J. Gomez, M.D., Ph.D.
   Chairman and CMO
   813-909-2029

        -or-

   Ron Stabiner
   The Wall Street Group, Inc.
   212-888-4848


DATASOURCE: DNAPrint genomics, Inc.



CONTACT:  Hector J. Gomez, Chairman and CMO, DNAPrint genomics,

[phone]; or Ron Stabiner of The Wall Street Group, Inc.,

[phone], for DNAPrint genomics



Web site:  http://www.dnaprint.com/ 

Copyright